Tag: Lp(a)

AMGEN ANNOUNCES CARDIOVASCULAR STUDY TO EVALUATE ASSOCIATION BETWEEN LIPOPROTEIN(a) AND CARDIOVASCULAR RISK IN AFRICAN AMERICANS

Coronary/Structural Heart by 0 comments

Unique Community-Based Partnership With the Association of Black Cardiologists and Morehouse School of Medicine to Identify Study Sites and Participants Observational Study to Better Understand Associations Between Lp(a) Levels and Atherosclerotic Cardiovascular Disease (ASCVD) in an Underrepresented Patient Population THOUSAND OAKS, Calif., Feb. […]

Continue Reading →

Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events

Coronary/Structural Heart by 0 comments

– Ionis-discovered pelacarsen continues to advance as potential first new therapy for Lp(a)-driven cardiovascular disease CARLSBAD, Calif., Aug. 2, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that pelacarsen, formerly known as AKCEA-APO(a)-LRx, and licensed by Novartis (NYSE: NVS) for exclusive worldwide development […]

Continue Reading →